

CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

UNAUDITED (CONSOLIDATED) FINANCIAL RESULTS FOR THE THREE MONTHS AND HAIF YEAR ENDED 30th SEPTEMBER 2019

Prepared in compliance with the Indian Accounting Standards (Ind - AS)

Particulars	Three Months Ended			Half Year Ended		Financial Year Ended
	30.09.2019	30.06.2019	30.09.2018	30.09.2019	30.09.2018	31.03.2019
	(1)	(2)	(3)	(4)	(5)	(6)
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	INR in lakhs					
Income:						
I Revenue from operations	22,720.34	19,255.32	15,586.30	41,975.66	30,232.29	64,869.09
II Other income	689.37	446.76	701.32	1,136.13	862.24	1,902.89
III Total Income (I+II)	23,409.71	19,702.08	16,287.61	43,111.79	31,094.53	66,771.98
IV Expenses:						
a. Cost of materials consumed	3,595.80	2,246.33	2,300.15	5,842.13	4,665.14	9,511.76
b. Purchase of traded goods	7,354.40	12,114.20	4,789.41	19,468.59	8,830.70	20,373.31
c. Changes in inventories of finished goods, stock in trade and work in progress	-7.17	-5,842.40	-62.61	-5,849.57	-59.62	(1,007.04)
d. Employee benefit expenses	1,595.84	1,558.82	1,146.12	3,154.66	2,298.52	4,710.97
e. Finance cost	8.01	1.00	1.95	9.00	3.17	6.00
f. Depreciation & Amortisation Expenses	740.52	738.67	557.84	1,479.19	1,103.17	2,342.50
g. Other Expenses	3,069.96	2,440.16	1,834.71	5,510.11	3,615.99	8,146.86
h. Total Expenses	16,357.34	13,256.78	10,567.58	29,614.11	20,457.07	44,084.36
V Profit before exceptional items and Tax (III-IV)	7,052.37	6,445.30	5,720.04	13,497.67	10,637.46	22,687.62
VI Exceptional items	-	-	-	-	-	-
VII Profit Before Tax (V-VI)	7,052.37	6,445.30	5,720.04	13,497.67	10,637.46	22,687.62
VIII Tax Expenses						
(1) Current Tax	1,334.03	1,449.66	1,146.66	2,783.69	2,095.21	5,485.70
(2) Deferred Tax	-8.72	-11.32	223.61	-20.04	453.07	(453.62)
Total Tax Expenses	1,325.31	1,438.35	1,370.27	2,763.65	2,548.28	5,032.08
IX Net Profit for the period (VII - VIII)	5,727.06	5,006.95	4,349.78	10,734.02	8,089.19	17,655.54
X Other Comprehensive Income - Net of Income Tax						
A. Items that will not be re-classified to profit or loss						
i) Remeasurements of Defined Benefit Plan	-9.97	(30.34)	22.84	(40.31)	36.89	(84.43)
B. Items that will be re-classified to profit or loss						
i) Exchange difference in translating the financial statements of foreign operations	461.52	(7.06)	308.86	454.46	298.44	58.86
XI Total Comprehensive Income For The Period (IX + X)	6,178.61	4,969.55	4,681.48	11,148.16	8,424.52	17,629.97
XII Profit attributable to:						
Owners of the Company	5,731.86	5,023.45	4,685.97	10,755.32	8,428.88	17,656.70
Non- controlling interests	-4.79	-16.51	(0.87)	(21.30)	(4.36)	(1.16)
Total Comprehensive Income For The Period attributable to	5,727.06	5,006.95	4,685.11	10,734.02	8,424.52	17,655.54
XIII Total Comprehensive Income For The Period attributable to						
Owners of the Company	6,183.40	4,986.06	4,692.04	11,169.46	8,438.58	17,631.13
Non- controlling interests	-4.79	(16.51)	(0.87)	(21.30)	(4.36)	(1.16)
	6,178.61	4,969.55	4,691.18	11,148.16	8,434.22	17,629.97
XIV Paid up Equity Share Capital (Face value of share of Rs 2/- each)	1,512.86	1,512.86	1,512.07	1,512.86	1,512.07	1,512.07
XV Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year						58,186.03
XVI Earnings Per Share (EPS) (Not annualised) based on face value Rs 2/- per Equity share						
(a) Basic (in Rupees)	7.58	6.59	6.21	14.22	11.16	23.35
(b) Diluted (in Rupees)	7.51	6.55	6.18	14.11	11.11	23.23

Notes :

1) The above results have been prepared in accordance with the Companies (Indian Accounting standards) Rules, 2015 ("Ind As") prescribed under Section 133 of the Companies Act, 2013 and other accounting pronouncement generally accepted in India, to the extent applicable.

2) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extraordinary item.

3) Effective April 01,2019 the company adopted Ind AS 116 "Leases" and applied the same to the lease contracts existing on April 01,2019 using the modified retrospective approach. The effect of the adoption is not significant to the results for the period.

4) Revenue from operations is disclosed net of Goods & Service Tax

5) The Consolidated financial results of the company have been reviewed and recommended by the Audit Committee of the Board and have been approved by the Board of Directors of the Company at their meeting held on 30th Oct' 2019

6) The Statutory Auditors of the Company have carried out limited review of the above Consolidated Financial Results pursuant to regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulations,2015.An unqualified opinion has been issued by them thereon.

7) During the quarter ended 30th Sep, 2019 the Company's wholly owned subsidiary Caplin Point Far East Limited, Hong Kong has acquired a majority share (98%) in Drogueria Saimed S.A., Honduras. The results of this subsidiary has been consolidated in the above results.

8) Inventories as at 30th Sep 2019 includes the Closing Inventories (along with Inventories-in-transit) of our subsidiary in Honduras which was acquired in the current quarter and the Inventories of our subsidiary in Nicaragua, El-Salvador and India. Hence this is not comparable with the previous periods

9) Prior year / period figures are regrouped / rearranged wherever necessary.

Place: Chennai

Dr Sridhar Ganesan

Date: 30th October, 2019

Managing Director

CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

UNAUDITED (STANDALONE) FINANCIAL RESULTS FOR THE THREE MONTHS AND HAIF YEAR ENDED 30th SEPTEMBER 2019

Prepared in compliance with the Indian Accounting Standards (Ind - AS)

	Particulars	Three Months Ended			Half Year Ended		Financial Year Ended
		30.09.2019	30.06.2019	30.09.2018	30.09.2019	30.09.2018	31.03.2019
		(1)	(2)	(3)	(4)	(5)	(6)
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
INR In Lakhs							
	Income:						
I	Revenue from operations	13,326.02	14,026.64	13,123.80	27,352.67	25,640.08	53,690.57
II	Other income	458.31	1,994.44	666.70	2,452.75	2,472.19	3,540.13
III	Total Income (I+II)	13,784.34	16,021.08	13,790.50	29,805.42	28,112.27	57,230.70
	Expenses:						
	a. Cost of materials consumed	3,085.17	2,048.94	2,300.15	5,134.11	4,665.14	9,404.33
	b. Purchase of traded goods	2,905.49	3,856.33	3,745.97	6,761.81	6,949.07	14,549.56
	c. Changes in inventories of finished goods, stock in trade and work in progress	-91.55	277.33	-62.61	185.78	-59.62	-250.61
	d. Employee benefit expenses	663.84	670.18	1,128.67	1,334.02	2,274.59	4,201.25
	e. Finance cost	7.00	1.20	1.95	8.20	3.17	5.98
	f. Depreciation & Amortisation Expenses	431.59	435.80	556.58	867.39	1,101.81	2,084.32
	g. Other Expenses	1,513.90	1,327.89	1,787.83	2,841.79	3,531.89	6,970.49
	h. Total Expenses	8,515.43	8,617.67	9,458.54	17,133.10	18,466.05	36,965.32
V	Profit before exceptional items and Tax (III-IV)	5,268.91	7,403.41	4,331.96	12,672.32	9,646.22	20,265.38
VI	Exceptional items	-	-	-	-	-	-
VII	Profit Before Tax (V-VI)	5,268.91	7,403.41	4,331.96	12,672.32	9,646.22	20,265.38
VIII	Tax Expenses						
	(1) Current Tax	1,215.47	1,319.73	1,146.30	2,535.20	2,094.85	5,410.63
	(2) Deferred Tax	74.10	73.12	223.61	147.22	453.07	38.10
	Total Tax Expenses	1,289.57	1,392.85	1,369.91	2,682.42	2,547.92	5,448.73
IX	Net Profit for the period (VII-VIII)	3,979.33	6,010.56	2,962.05	9,989.89	7,098.30	14,816.65
X	Other Comprehensive Income/ (Loss) - Net of Income Tax						
	A. Items that will not be re-classified to profit or loss						
	i) Remeasurements of Defined Benefit Plan	(6.57)	(12.63)	22.84	(19.20)	36.89	(71.93)
XI	Total Comprehensive Income For The Period (IX+X)	3,972.77	5,997.93	2,984.89	9,970.70	7,135.19	14,744.72
XII	Paid up Equity Share Capital (Face value of shares of Rs 2/- each)	1,512.86	1,512.86	1,512.07	1,512.86	1,512.07	1,512.61
XIII	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-	-	-	-	-	41,691.88
XIV	Earnings Per Share (EPS) (Not annualised) based on face value Rs 2/- per Equity share						
	(a) Basic (in Rupees)	5.26	7.95	3.95	13.21	9.44	19.60
	(b) Diluted (in Rupees)	5.22	7.90	3.93	13.12	9.39	19.50

Notes :

- 1) This statement has been prepared in accordance with the Companies (Indian Accounting standards) Rules, 2015 ("Ind As") prescribed under Section 133 of the Companies Act, 2013 and other accounting pronouncement generally accepted in India, to the extent applicable.
- 2) The standalone financial results of the Company have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meeting held on 30th October, 2019.
- 3) The Statutory Auditors of the Company have carried out limited review of the above Standalone Financial Results pursuant to regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulations, 2015. An unqualified opinion has been issued by them thereon.
- 4) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
- 5) Effective April 01, 2019 the company has adopted Ind AS 116 "Leases" and applied the same to the lease contracts existing on April 01, 2019 using the modified retrospective approach. The effect of the adoption is not significant to the results for the period.
- 6) Revenue from operations is disclosed net of Goods and Service Tax
- 7) Other Income and Profits Before Tax for the Quarter ended 30th June 2019 includes Dividend of Rs. 1753.01 lacs received from our wholly owned subsidiary Caplin Point Far East Limited, Hong Kong. The same is NIL for the Quarter ended 30th Sep' 2019
- 8) Pursuant to the Business Transfer Agreement executed by the Company on 18th January, 2019, the regulated markets injectable business (including USFDA approved injectable plant and DSIR recognized R&D Units CP4 & CP5) have been transferred to its wholly owned subsidiary company, Caplin Steriles Limited. Hence the results of the current quarter ended 30th September, 2019 are not comparable with the corresponding previous periods
- 9) Prior year / period figures are regrouped / rearranged wherever necessary.

Place: Chennai

Date: 30th October 2019

Dr Sridhar Ganesan
Managing Director